Importantly, RDD1 was found to be of broad prognostic relevance, with low RDD1 mRNA levels correlating with poor survival across a range of solid tumors, including ovarian, lung, gastric, liver, kidney cancers and sarcomas, as well as a marker of clinical response to paclitaxel.[103] The precise functional roles of RDD1 and other newly identified targets in cancer cell survival and resistance are yet to be elucidated, with detailed characterization underway. Here, C1orf115 is linked to kidney cancer.